A comparative study of the impact of prescription and non-prescription mucolytic agents on respiratory disease management in a community-based population.
文献摘要
Introduction Respiratory disease significantly impacts quality of life at the same time economic burden. Mucolytic agents are widely used in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and upper respiratory tract infections (URTIs). However, real-world differences in clinical outcomes between prescription-guided and over-the-counter (OTC) mucolytic use in community settings remain inadequately characterized. Objective The present study aimed to compare symptom improvement and adverse effects between prescription based and OTC mucolytic users, and to evaluate patterns of usage and healthcare seeking behaviour consultation in a community setting. Methods A longitudinal observational study conducted among 200 participants categorized into OTC and prescription groups conducted after getting institutional Ethical approval (BVDUMC/IEC/399/25-26). Data collected using structured questionnaires assessing symptom scores, adverse effects, and healthcare utilization. Statistical analysis included descriptive statistics and Chi-square test. A p value of Results The prescription group demonstrated a statistically significant improvement in symptoms, with mean COPD Assessment Test (CAT) scores decreasing from 21 to 18 (p p Conclusion Prescription mucolytic therapy demonstrated better outcomes compared to OTC use, likely due to structured treatment and medical supervision. These findings indicate the importance of rational prescribing and patient education in respiratory disease management.